Cargando…
Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab
Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible s...
Autores principales: | Abdelmaseih, Ramy, Abdelmasih, Randa, Hasan, Mustajab, Hamza, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260193/ https://www.ncbi.nlm.nih.gov/pubmed/34262805 http://dx.doi.org/10.7759/cureus.15467 |
Ejemplares similares
-
Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review
por: Abdelmaseih, Ramy, et al.
Publicado: (2020) -
Uncommon Pathogen in an Unexpected Host: A Rare Case of Rothia mucilaginosa Infective Endocarditis in an Immunocompetent Patient Without an Underlying Valvular Disease
por: Abdelmaseih, Ramy, et al.
Publicado: (2021) -
Atrial Myxoma, a Rare Cause of Sudden Cardiac Death: A Case Report and Review of Literature
por: Hasan, Mustajab, et al.
Publicado: (2020) -
A Case of Hypokalemic Periodic Paralysis in a Young Athlete
por: Abdelmasih, Randa, et al.
Publicado: (2021) -
A Rare Case of Massive Pericardial Effusion as the First Presentation of Hashimoto’s Hypothyroidism With Complete Resolution With Levothyroxine Treatment - A Case Report
por: Abdelmasih, Randa, et al.
Publicado: (2021)